Radioligand Therapy Shows Consistent Efficacy in Metastatic Prostate Cancer

Novartis announced that its radioligand therapy, Pluvicto™, has consistently improved radiographic progression-free survival across various patient groups with PSMA-positive metastatic hormone-sensitive prostate cancer. These data, presented at the ASCO Annual Meeting, underscore the broad clinical utility of Pluvicto™. The findings represent a continued advancement in the treatment of metastatic prostate cancer.